Successful Tactics for Introducing New Databases to CDC Library Patrons: A Case Study

When libraries subscribe to new resources, encouraging patrons’ adoption of these services can be challenging. Moreover, when the resource offers access to a service or information type that is relatively unknown amongst patrons, such as altmetrics, the challenge is even greater. Altmetrics are data from the social web that can be used to track discussions and reuse of scientific outputs (journal articles, books, data sets, presentations, and beyond) across a variety of platforms like news outlets, scholarly peer review websites, social media, scholarly reference managers, and public policy documents. Promoting, consulting and conducting workshops are just some of the methods that libraries stimulate use of new resources. Some approaches work better than others. In this paper, we discuss the joint approach of the Stephen B. Thacker Centers for Disease Control and Prevention’s (CDC) Library training team and Altmetric to promote the use of an altmetrics database, Altmetric Explorer for Institutions, amongst CDC staff. These organizations worked together closely to offer training and consultations, each with complementary approaches

Discovery of 6‑Amino-2-{[(1<i>S</i>)‑1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro‑8<i>H</i>‑purin-8-one (GSK2245035), a Highly Potent and Selective Intranasal Toll-Like Receptor 7 Agonist for the Treatment of Asthma

Induction of IFNα in the upper airways via activation of TLR7 represents a novel immunomodulatory approach to the treatment of allergic asthma. Exploration of 8-oxoadenine derivatives bearing saturated oxygen or nitrogen heterocycles in the <i>N</i>-9 substituent has revealed a remarkable selective enhancement in IFNα inducing potency in the nitrogen series. Further potency enhancement was achieved with the novel (<i>S</i>)-pentyloxy substitution at <i>C</i>-2 leading to the selection of GSK2245035 (<b>32</b>) as an intranasal development candidate. In human cell cultures, compound <b>32</b> resulted in suppression of Th2 cytokine responses to allergens, while <i>in vivo</i> intranasal administration at very low doses led to local upregulation of TLR7-mediated cytokines (IP-10). Target engagement was confirmed in humans following single intranasal doses of <b>32</b> of ≥20 ng, and reproducible pharmacological response was demonstrated following repeat intranasal dosing at weekly intervals